Welcome to LookChem.com Sign In|Join Free

CAS

  • or

56180-94-0

Post Buying Request

56180-94-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

56180-94-0 Usage

Overview

Acarbose is an alpha-glucosidase inhibitor drug that is used in the treatment of type 2 diabetes mellitus. It is normally given to patients who are non-insulin dependent where oral hypoglycemic agents or diet modification do not control their condition. The drug is commonly sold in China and Europe as Glocobay while in North America it is sold using the Precose brand name. Acarbose is an oligosaccharide that is normally formed by the process of fermenting a microorganism known as Actinoplanes utahensis. The drug is white and is soluble in water.

Pharmacology

Acarbose acts by delaying the digestion of consumed carbohydrates, leading to a small increase in blood sugar levels. Acarbose minimizes the concentrations of glycosylated hemoglobin in patients with type 2 mellitus.

Mechanism of Action

Acarbose does not enhance the secretion of insulin, which is in contrast to sulfonylureas. The drug’s antihyperglycemic action is because of competitive, reversible inhibition of pancreatic alpha-amylase and intestinal alpha-glucoside hydrolase enzymes that are membrane-bound. On one hand, the membrane-bound intestinal alpha-glucosidases hydrolyze trisaccharides, disaccharides, and oligosaccharides to glucose as well as other monosaccharides in the small intestine’s brush border. Through this enzyme inhibition in diabetic patients, postprandial hyperglycemia is lowered and glucose absorption is delayed.Acarbose is a complex oligosaccharide that acts as a competitive, reversible inhibitor of pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolase. Pancreatic alpha-amylase hydrolyzes complex carbohydrates to oligosaccharides in the small intestine.https://www.ncbi.nlm.nih.gov

Information on Dosing

Acarbose acts by preventing the digestion of complex carbohydrates; therefore, it should be administered orally at the start (with the first bite) of every meal, three times a day. It is important to note that patients should adhere to dietary instructions, regular testing of blood and urine glucose levels as well as regular exercise. However, Acarbose does not lead to hypoglycemia even when patients take it in a fasted state. Conversely, Acarbose is administered in combination with sulfonylurea drugs and insulin, thus can lead to low blood sugar, increasing the hypoglycemic potential of these agents. It is noteworthy that Acarbose dosage should always be individualized based on both tolerance and effectiveness but not exceeding the maximum recommended dose of 100mg.t.i.d depending on the patient’s weight. In addition, if the prescribed diet is not adhered to, side effects in the intestines might increase. During the initiation of treatment, therapeutic response to Acarbose can be determined by one-hour postprandial plasma glucose as well as identifying the maximum effective dose for a specific patient. Glycosylated hemoglobin should then be measured at intervals of about three months, The main aim of using Acarbose is to reduce glycosylated hemoglobin and postprandial plasma glucose levels to near normal by administering the lowest effective dose.

Acarbose Warnings

Before administering Acarbose to a patient, the doctor must ensure that the patient has ever had cirrhosis of the liver or any other liver disease, an inflammatory disease, or ketoacidosis. Acarbose is contraindicated in individuals that are known to exhibit hypersensitivity to the drug. In particular, patients with diabetic cirrhosis or ketoacidosis. The drug is also contraindicated in people with colonic ulceration, inflammatory bowel disease, and partial intestinal obstruction. Furthermore, Acarbose is contraindicated in individuals with intestinal disorders as well as conditions that may deteriorate due to increased levels of gas in the intestine. Patients should inform the doctor or health worker that they are on Acarbose medication before having any surgery. Pregnant women should not also take the drug unless prescribed by a doctor.

Side effects

Side effects normally develop during the first weeks of using the drug. Notably, they are primarily mild-to-moderate gastrointestinal effects.One of the major side effects of Acarbose is the delivery of the remaining carbohydrate after degradation of some into glucose to the colon. Studies have revealed that 78% who use Acarbose experience flatulence and diarrhea as a result of digestion of the complex carbohydrates in the colon.Most Acarbose effects are dose-related, therefore, it is advisable to begin with small dosage first and gradually increasing to the required amount of dose. The initial dosage is 25 mg t.i.d, which commonly given three times a day. After 4-8 weeks intervals, the maintenance dosage can be increased to 50mg t.i.d. The maximum dosage is 50mg t.i.d for patients who weigh less than 60kg while for those weighing above 60kg, it should be a maximum of 100 mg t.i.d. it is noteworthy that studies have indicated that gastrointestinal side effects can decrease from 50% to 15% over the intervals or even at the maintenance dosing stage.A doctor or physician should be immediately called if a patient suffers from hyperglycemia. The patient can also eat food comprising of monosaccharides such as gel or glucose tablet.The doctor should be informed immediately if a patient is experiencing fevers, unusual stress, and illness when taking Acarbose since such events typically lead to a change of blood sugar levels thus affecting the required dosage.Studies have revealed that Acarbose can help patients with diabetes to lose weight.Severe Acarbose side effects include severe itching, constipation, unusual bleeding, and yellowing of eyes and skin.https://www.rxlist.com/precose-side-effects-drug-center.htm

Description

Acarbose, a complex oligosaccharide isolated from Actinoplanes, is reportedly useful as an adjuvant therapy in diabetes. By inhibiting alpha-glucosidase, acarbose delays carbohydrate metabolism in the gastrointestinal tract and modulates changes in food induced blood sugar levels.

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 56180-94-0 differently. You can refer to the following data:
1. A reversible alpha-glucosidase inhibitorAcarbose is used as a reversible alfa-glucosidase inhibitor. It acts as an anti-diabetic drug, which finds useful application to treat type 2 diabetes mellitus and prediabetes. It is also employed for Hepatitis. It also acts as a beta glucosidase inhibitor, antihyperlipidaemia and antiobesity.
2. antipsychotic: 5HT antagonist, dopamine antagonist, H1-antihistamine, alpha adrenergic blocker
3. Acarbose is pseudo-oligosaccharide with a terminal C7-cyclitol patented in 1975 by Bayer. Acarbose is a component of the amylostatin complex produced by a species of Actinoplanes and Streptomyces. Acarbose acts as a potent inhibitor of alpha-glucosidases and saccharases. Since 1990, acarbose has been used therapeutically for the treatment of type 2 diabetes.

Definition

ChEBI: A tetrasaccharide derivative consisting of a dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl C7 cyclitol moiety [called valienol (or valienamine)] linked via nitrogen to isomaltotriose.

Manufacturing Process

The title compound was obtained from a cultural broth of fermenting a microorganism of family Actinoplanaceae in particular of strain genus Actinoplanes, according to DT-OS (German Published Specification) No. 2,347,782. 50 g of cation exchange resin (Lewatit S 1040W) in the H+ form and 30 g an anion exchanger (Lewatit M 600) in OH form were added to 300 ml of a culture broth with mycelium content of 25% and an inhibitor content of 50 SIU/ml in solution. The mixture was stirred at room temperature for 50 minutes. The solution, containing a sieving nozzle with 0.1 mm slits. For testing, a sample of filtered broth was centrifuged and was examined for saccharase inhibitor in the supernatant liquor. The solution contained 2.5 SIU/ml, that is to say 5%, of starting activity. This procedure improved the yield of the aminosugar from 20% in the procedure known from DT-OS (German Published Specification) No. 2,347,782, to 50-60%. It has now found that cation exchangers based on styrene, divinylbenzene and methoxymethylmethacrylamide, oxyethyl(meth)acrylic acid amide (ester), dimethylaminoethyl(meth)acrylic acid amide (ester) or oxypropyl(meth)acrylic acid amide(ester) are preferred in industrial separation procedure of acarbose. This exchanger gave a very sharp separation of the individual homologues and impurities. And it has now found the new biosynthesis of acarbose by using of gen engineering methods.

Brand name

Precose (Bayer);Glucobay.

Therapeutic Function

Antidiabetic

World Health Organization (WHO)

Acarbose, ana-glucosidase inhibitor, is used as an adjunctive therapy in the control of postprandial hyperglycaemia in non-insulin-dependent diabetes mellitus. Use of two or more hypoglycaemic drugs is not recommended.

General Description

Acarbose is a naturally occurring oligosaccharide,which is obtained from the microorganism Actinoplanes utahensis. It is a white to off-white powder that is soluble in water and has a pKa of 5.1. As one mightexpect, its affinity for α-glucosidase is based on it being apolysaccharide that the enzyme attempts to hydrolyze. Thisallows acarbose to act as a competitive inhibitor, which inturn reduces the intestinal absorption of starch, dextrin, anddissacharides.It is sold as 25-, 50-, and 100-mg tablets (Precose,generics) dosed with the first bite of each meal, up to t.i.d. Acarbose potently inhibits the glucoamylase activity of MGAM α-glucosidases and the sucrase activity of α-glucosidases, where as isomaltase activity is at most moderately inhibited at concentrations in the range of those in theintestinal lumen upon oral dosing, and trehalase and lactaseare not significantly inhibited. Some inhibition of pancreaticα-amylases may also contribute to the clinical effects.https://www.sciencedirect.com

Biochem/physiol Actions

Modified tetrasaccharide that acts as a reversible α -glucosidase inhibitor.

Clinical Use

Based on the structure of acarbose, it should come as nosurprise that little intact acarbose reaches the systemic circulation;instead, acarbose is extensively biotransformed by the actionof microbes and digestive enzymes in the gut. Only about35% of the radioactivity in a dose of 14C-labeled acarbose administeredorally to men was excreted in the urine, appearingas several metabolites, some of which are phase II conversionproducts of 4-methylpyrogallol (O-methyl, O-sulfate, orO-glucuronide conjugates); the methylpyrogallol fragmentarises from the terminal valienamine pseudosugar. That thesebiotransformation products are mostly formed in the gut isshown by the fact that nearly 90% of an intravenously administereddose of acarbose is excreted intact in urine.

Safety Profile

Low toxicity by ingestion,subcutaneous, and intravenous routes. Human systemiceffects: liver function impaired. When heated todecomposition it emits toxic vapors of NOx.

Veterinary Drugs and Treatments

May be useful for mild reductions in blood glucose concentrations (250 – 350 mg/dl range) in dogs and cats with non-insulin-dependent diabetes mellitus and as adjunctive treatment of insulin dependent diabetes mellitus.

Drug interactions

Potentially hazardous interactions with other drugs Antibacterials: hypoglycaemic effect possibly enhanced and increased gastrointestinal side effects with neomycin. Lipid lowering agents: hypoglycaemic effect possibly enhanced by colestyramine.

Metabolism

Oral bioavailability is 1-2%. After oral administration of the 14C-labelled substance, on average, 35% of the total radioactivity was excreted by the kidneys within 96 hours. The proportion of drug excreted in the urine was 1.7% of the administered dose. 50% of the activity was eliminated within 96 hours in the faeces.

Check Digit Verification of cas no

The CAS Registry Mumber 56180-94-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,1,8 and 0 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 56180-94:
(7*5)+(6*6)+(5*1)+(4*8)+(3*0)+(2*9)+(1*4)=130
130 % 10 = 0
So 56180-94-0 is a valid CAS Registry Number.
InChI:InChI=1/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3

56180-94-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (A2485)  Acarbose Hydrate  >98.0%(HPLC)(N)

  • 56180-94-0

  • 1g

  • 1,100.00CNY

  • Detail
  • TCI America

  • (A2485)  Acarbose Hydrate  >98.0%(HPLC)(N)

  • 56180-94-0

  • 5g

  • 3,870.00CNY

  • Detail
  • Sigma-Aldrich

  • (Y0000354)  Acarbose for identification  European Pharmacopoeia (EP) Reference Standard

  • 56180-94-0

  • Y0000354

  • 1,880.19CNY

  • Detail

56180-94-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name acarbose

1.2 Other means of identification

Product number -
Other names bay-g5421

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:56180-94-0 SDS

56180-94-0Relevant articles and documents

Purification process for manufacturing a high pure acarbose

-

Page/Page column 4, (2008/06/13)

A process for purifying and preparing highly pure acarbose from acarbose-containing fermentation broth. The acarbose is purified through steps of alcohol precipitation, a strongly acidic cation exchanger chromatography and an immobolized enzyme affinity chromatography. Acarbose is generally applied in treating diabetes.

Total Synthesis of Acarbose and Adiposin-2

Ogawa, Seiichiro,Shibata, Yasushi

, p. 605 - 606 (2007/10/02)

The first complete synthesis of acarbose (1a), the pseudotetrasaccharidic α-amylase inhibitor, is reported: coupling of the protected (+)-valienamine (16) and the epoxide (9) derived from 1'',6''-anhydromaltotriose (3), followed by deprotection; likewise, adiposin-2 (2a), the 6'-hydroxy analogue of (1a), has also been synthesised.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 56180-94-0